Serum Magnesium and Vascular Calcification

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

400 participants

Study Classification

OBSERVATIONAL

Study Start Date

2011-02-28

Study Completion Date

2011-05-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Both Kidney transplantation (KT) and Chronic Kidney Disease (CKD) patients have reduced kidney function. Low serum magnesium is more prevalent in KT recipients. The present study examines the difference in vascular calcification between KT and CKD and its association with serum magnesium.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Effect of Oral Magnesium on Vascular Calcification in Chronic Kidney Disease

NCT02542319

Chronic Kidney Disease Vascular Calcification Uremic Osteodystrophy

COMPLETED PHASE2

Sclerostin and Vascular Calcification in CKD and Renal Transplant

NCT04066855

Vascular Calcification Chronic Kidney Failure

UNKNOWN

Sevelamer, FGF-23 and Endothelial Dysfunction in Chronic Kidney Disease (CKD)

NCT01135615

We Investigated the Relationship Between Plasma FGF23 Levels and Endothelial Dysfunction in a Sizable Series of Incident Stage 3-4 CKD Patients.

COMPLETED PHASE4

Serum iPTH, Calcium and Phosphate, and the Risk of Mortality in Beijing Elderly Hemodialysis Population

NCT03261154

End Stage Renal Disease

COMPLETED

The Effect of Increasing Dialysate Magnesium on Calcification Propensity in Subjects on Haemodialysis

NCT02977117

Endstage Renal Disease

COMPLETED PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Kidney transplantation (KT) improved quality of life and longevity of CKD patients. Nevertheless, kidney function deteriorates overtime in a manner not different from CKD counterparts. Hypomagnesemia is prevalent in KT recipients secondary to immunosuppressive therapy. In addition to serum calcium, phosphate and elemental calcium intake, the relationship between low serum magnesium and vascular calcification (VC) has been observed in small studies in CKD. Whether low serum magnesium associates with VC in KT has never been elucidated. The present study compares vascular calcification between KT and CKD and its association with serum magnesium.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Vascular Calcification Chronic Kidney Disease

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_CONTROL

Study Time Perspective

CROSS_SECTIONAL

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Kidney transplant recipients

No interventions assigned to this group

Chronic kidney disease

No interventions assigned to this group

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* kidney transplant recipients at least 1 year post surgery
* predialysis chronic kidney disease with serum creatinine \> 1.1 mg/dL in female and 1.3 mg/dL in male